ARTICLE | Company News
Incyte, AstraZeneca deal
January 25, 2016 8:00 AM UTC
The companies partnered to conduct a Phase I/II trial to evaluate Incyte’s INCB39110 with AstraZeneca’s Tagrisso osimertinib as second-line treatment of EGFR T790M mutation-positive non-small cell ...